Gujarat Kidney and Super Speciality Hospital ne Q2 mein kamaal dikhaya hai! Consolidated profit **₹6.60 crore** tak pahunch gaya hai, jo last year **₹2.88 crore** tha. Lekin standalone numbers mein thodi girawat hai, jo investors ko notice karni chahiye.
Number game: Consolidated vs Standalone
Is baar Gujarat Kidney ke results mein mixed signals hain. Company ka consolidated Profit After Tax (PAT) ₹6.60 crore raha, jo pichle saal ke ₹2.88 crore ke muqable kaafi badhiya hai. Revenue ki baat karein toh, ye ₹12.93 crore se badhkar seedha ₹38.09 crore par pahunch gaya hai.
Lekin asli kahani standalone numbers mein chupi hai. Yahan revenue ₹9.64 crore se girkar ₹8.04 crore ho gaya hai aur profit bhi ₹2.30 crore se gharkar ₹1.78 crore par aa gaya hai. Iska matlab saaf hai—growth sirf subsidiaries ki wajah se dikh rahi hai, core business mein abhi thoda stress hai.
Auditor ka verdict
M/s. Y M Shah & Co. ne results ka limited review kiya hai aur audit report 'unmodified' hai, matlab financials mein koi gadbad nahi mili hai.
Investors ke liye kya hai insight?
Ab aapko sirf headline profit nahi dekhna hai. Ye track karna zaroori hai ki company apne main hospital operations (standalone) ko wapas track par kaise laati hai. Subsidiaries se aane wali growth sustainable hai ya nahi, ye aane wale quarters mein clear ho jayega.